LoginRegister

    Alkem Labs gets 2 USFDA observations for Daman facility

    Medical Dialogues BureauWritten by Medical Dialogues Bureau   |  

    New Delhi: Drugmaker Alkem Laboratories (Alkem Labs) recently informed that the company has received two observations from the US health regulator for its manufacturing facility situated at Daman, India.


    The facility was inspected from August 26, 2019, to August 30 2019.

    "This is to inform you that the US FDA had conducted an inspection at the Company's manufacturing facility located at Daman, India from 26th August 2019 to 30th August 2019," Alkem said in a BSE filing.


    Also Read: Alkem Labs gets 8 USFDA observations for St Louis facility

    At the end of the inspection, the Company has received a Form 483 with two (2) observations.


    "The Company shall put together a detailed response with adequate corrective and preventive measures to address the US FDA observations and the same is proposed to be filed within the timeline stipulated by the USFDA," Alkem added in the filing.


    Established in 1973, Alkem Laboratories has a portfolio of over 700 brands covering all major therapeutic segments. It has 16 manufacturing facilities, 14 being in India and two in the United States.

    Read Also: Alkem Labs gets 4 USFDA observations for St Louis facility

    Alkemalkem damanalkem daman plantAlkem LabsAlkem manufacturing facilitiesAlkem US plantDaman facilityform 483pharmapharma companypharma newspharma news indiaUSFDAusfda 483USFDA form 483USFDA inspectionUSFDA observations

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X